Marina Hahn - Vapotherm Independent Director
| VAPODelisted Stock | USD 0.40 0.00 0.00% |
Insider
Marina Hahn is Independent Director of Vapotherm since 2017.
| Age | 61 |
| Tenure | 7 years |
| Phone | 603 658-0011 |
| Web | www.vapotherm.com |
Vapotherm Management Efficiency
The company has return on total asset (ROA) of (0.3139) % which means that it has lost $0.3139 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.8669) %, meaning that it created substantial loss on money invested by shareholders. Vapotherm's management efficiency ratios could be used to measure how well Vapotherm manages its routine affairs as well as how well it operates its assets and liabilities.Vapotherm currently holds 99.31 M in liabilities with Debt to Equity (D/E) ratio of 7.19, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vapotherm has a current ratio of 5.18, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Vapotherm until it has trouble settling it off, either with new capital or with free cash flow. So, Vapotherm's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vapotherm sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vapotherm to invest in growth at high rates of return. When we think about Vapotherm's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Chi Nguyen | Neuropace | 47 | |
| Danielle Watson | Heart Test Laboratories | 42 | |
| RaeAnn Byrnes | Vivos Therapeutics | N/A | |
| Shunichi Kuroda | Bone Biologics Corp | N/A | |
| Mark MD | Bluejay Diagnostics | N/A | |
| Jason Cook | Bluejay Diagnostics | 42 | |
| Mark Feinberg | Bluejay Diagnostics | N/A | |
| Sanjay Ahuja | Tivic Health Systems | N/A | |
| Keith Simeone | STRATA Skin Sciences | N/A | |
| Veronica Cai | Tivic Health Systems | 48 | |
| Martha Morrell | Neuropace | 67 | |
| Nikolai Kabelev | STRATA Skin Sciences | 48 | |
| Julie Gannon | Vivos Therapeutics | N/A | |
| Kirk Huntsman | Vivos Therapeutics | 66 | |
| Joel Bradus | Nexalin Technology | N/A | |
| Michael Favet | Neuropace | 54 | |
| Bradford Amman | Vivos Therapeutics | 62 | |
| David MD | Sight Sciences | 54 | |
| Mark Saxton | Neuropace | 59 | |
| Jennifer Ernst | Tivic Health Systems | 56 | |
| Todd Huntsman | Vivos Therapeutics | N/A | |
Management Performance
| Return On Equity | -6.87 | |||
| Return On Asset | -0.31 |
Vapotherm Leadership Team
Elected by the shareholders, the Vapotherm's board of directors comprises two types of representatives: Vapotherm inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vapotherm. The board's role is to monitor Vapotherm's management team and ensure that shareholders' interests are well served. Vapotherm's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vapotherm's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Pres CEO | ||
| John Landry, Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer | ||
| Elizabeth Weatherman, Independent Director | ||
| Lance Berry, Independent Director | ||
| James Lightman, Gen VP | ||
| Lori Knowles, Director | ||
| Dorota Mckay, Chief Accounting Officer, Controller | ||
| James Liken, Independent Chairman of the Board | ||
| Marina Hahn, Independent Director | ||
| Gregoire Ramade, Senior Vice President, Chief Commercial Officer | ||
| Anthony Arnerich, Independent Director | ||
| William Niland, Founder | ||
| Brian Lawrence, Senior Vice President, Chief Technology Officer | ||
| Joseph Army, President, Chief Executive Officer, Director | ||
| Mary Moynihan, Director | ||
| Anthony Haagen, VP Compliance | ||
| FAAP MD, VP Officer | ||
| Donald Spence, Independent Director | ||
| Lindsay Becker, Vice President of Human Resources |
Vapotherm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Vapotherm a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.87 | |||
| Return On Asset | -0.31 | |||
| Profit Margin | (1.03) % | |||
| Operating Margin | (0.63) % | |||
| Current Valuation | 102.76 M | |||
| Shares Outstanding | 6.14 M | |||
| Shares Owned By Insiders | 16.59 % | |||
| Shares Owned By Institutions | 48.13 % | |||
| Number Of Shares Shorted | 472.25 K | |||
| Price To Book | 7.11 X |
Pair Trading with Vapotherm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vapotherm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vapotherm will appreciate offsetting losses from the drop in the long position's value.Moving together with Vapotherm OTC Stock
Moving against Vapotherm OTC Stock
| 0.72 | BAC | Bank of America Aggressive Push | PairCorr |
| 0.55 | WMT | Walmart Aggressive Push | PairCorr |
| 0.53 | CSCO | Cisco Systems Aggressive Push | PairCorr |
| 0.48 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
| 0.45 | TRV | The Travelers Companies Fiscal Year End 17th of January 2025 | PairCorr |
The ability to find closely correlated positions to Vapotherm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vapotherm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vapotherm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vapotherm to buy it.
The correlation of Vapotherm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vapotherm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vapotherm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vapotherm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Vapotherm OTC Stock
If you are still planning to invest in Vapotherm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vapotherm's history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |